JT

Jim Tananbaum

Founder of Foresite Capital Management

San Francisco, California

Overview

Work Experience

  • Founder and CEO

    2010 - Current

    Founder, CEO and managing director of a multi-stage healthcare and life sciences investment firm, and chief architect of its rigorous scientific and data-driven approach to investment analysis. Foresite Capital aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles.

  • Co-Founder and Managing Director PVP2 & PVP3

    2001 - 2010

    $1B healthcare venture capital group focussed on series A financings.

  • Co-Founder and Chief Executive Officer

    1997 - 2000

    http://www.theravance.com/ and http://www.inva.com/

  • Partner

    1994 - 1997

    Built Healthcare Service Investment practice. Led investments in Amerigroup, Healtheon, CareSelect (through Intensiva), and Novamed.

  • Co-Founder. Board Member.

    1991 - 1997

    Founded GelTex while finishing my Harvard degree, running the firm out of my garage for the first year. I recruited co-founder Professor George Whitesides from the Harvard Chemistry Department. Their product, Renvela, has helped more patients with renal failure than almost any drug in the world since its conception in 1991. The GelTex team also conceived of Cholestogel, which helped patients with high cholesterol that could not take other cholesterol reducing products. GelTex was sold to Genzyme, which was bought by Sanofi.

  • Product Manager, Prilosec

    1991 - 1993

    Primary architect of Prilosec GP strategy. Developed marketing campaign around promoting the use of Prilosec on patients with symptoms that had been treated with H2 antagonists (the previous market leaders). Pioneered using physician identified perscription data to focus marketing campaign on MDs that were top anti-ulcer prescribers.

Relevant Websites